Summary
Melphalan pharmacokinetics were studied in 20 children with stage IV neuroblastomas or Ewing's sarcomas and in 10 adults with AML, ALL, or small cell lung carcinomas, after IV administration of high doses (140 mg/m2 with furosemide-induced diuresis and 180 mg/m2 without induced diuresis) and high fluid intake (3000 ml/m2/day).
Unchanged melphalan was assayed in plasma and cereorospinal fluid by means of a high-performance liquid chromatographic procedure. The elimination half-life (t1/280 min) allows autologous bone marrow transplantation 24 h after the drug administration. In some children we were able to detect melphalan in cerebrospinal fluid samples.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts DS, Chang SY, Chen HSG, et al (1979) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26:73
Alexanian R, Bergsagel DE, Migliore PJ, et al (1968) Melphalan therapy for plasma cell myeloma. Blood 31:1
Bosanquet AG, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18:355
Chang SY, Alberts DS, Farquhar D, et al (1978a) Hydrolysis and protein binding of melphalan. J Pharm Sci 67:682
Chang SY, Alberts DS, Melnick LR, et al (1978b) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67:679
D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115
Davis TP, Peng YM, Goodman GC, Alberts DS (1982) HPLC, MS and pharmacokinetics of melphalan, bisantrene and 13-cis-retinoic acid. J Chromatogr Sci 20:511
Egan CM, Jones CR, McCluskey M (1981) Method for the measurement of melphalan in biological samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr 224:338
Furner RL, Mellet LB, Brown RK, Duncan G (1976) A method for the measurement of L-phenylalanine mustard in the mouse and the dog by high-pressure liquid chromatography. Drug Metab Dispos 4:577
Gouyette A (1983) Pharmacokinetics: statistical moment calculations. Arzneimittelforsch 33:173
Hedley DW, McElwain TJ, Millar JL, Gordon MY (1978) Acceleration of bone-marrow recovery by pretreatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet II:966
Lazarus HM, Herzig RH, Graham-Pole J, et al (1983) Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359
McElwain TJ, Hedley DW, Gordon MY, et al. (1979) High-dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 7 [suppl 5]:360
Niskanen E (1983) Preservation of human granulopoietic precursors following storage in the non-frozen state. Transplantation 36:341
Pallante SL, Fenselau C, Mennel RG, et al (1980) Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients. Cancer Res 40:2268
Smith JP, Rutledge F (1975) Advances in chemotherapy for gynecologic cancer. Cancer 36:669
Taha IAK, Ahmad RA, Rogers DW, et al (1983) Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol 10:212
Tattersall MHN, Jarman M, Newlands ES, et al (1978) Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14:503
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gouyette, A., Hartmann, O. & Pico, JL. Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother. Pharmacol. 16, 184–189 (1986). https://doi.org/10.1007/BF00256174
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256174